

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

VERVAET et al.

Serial No. 10/537,301

Filed: June 2, 2005

For: PHARMACEUTICAL COMPOSITIONS OF CELL LYSATE
AND PROCESSES FOR THE PRODUCTION AND USE
THEREOF



Atty. Ref.: 2551-170

Group: 1651

Examiner: Singh

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

July 25, 2006

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☐ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☒ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

- ☐ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☒ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☒ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: _____



B. J. Sadoff

Reg. No. 36,663

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

2551-170

APPLICANT

VERVAET et al.

FILING DATE

June 2, 2005


SERIAL NO.

10/537,301

GROUP

1651

(Use several sheets if necessary)

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Hodge et al, "Flocculation of Bacteria by Hydrophilic Colloids", August 29, 1957, Vol. 75, pp 258-264
	Tempio et al, J. Pharm. Sci., 1980 Oct; 69(10):1209-14 (Abstract)
	Vanapalji et al, Journal of Agricultural and Food Chemistry 50 (18):5224-5228 Aug. 28, 2002 (Abstract)
	Ye et al, Journal of Agricultural and Food Chemistry 52 (17):5491-5498, Aug. 25, 2004 (Abstract)
	Zatz et al, International Journal of Pharmaceutics, Vol. 9, Issue 4, October 1981, pgs 315-319 (Abstract)
	Velez et al, Journal of Agricultural and Food Chemistry 51(1):265-269, January 1, 2003 (Abstract)
	Quintana et al, Journal of Texture Studies 33(3):215-236, September 2002 (Abstract)
	Hemar et al, Food Hydrocolloids 15(4-6):513-519, July - Nov., 2001 (Abstract)
	Singh et al, Current Science 78(7):798-803, April 10, 2000 (Abstract)
	Koczko et al, Food Hydrocolloids 12(1):43-53, Jan. 1998 (Abstract)
	Zatz et al, International Journal of Pharmaceutics 9(4):315-319, 1981 (Abstract)

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)